8-K current report · filed Nov 9, 2026

NovoCure Ltd (NVCR) 8-K Current Report: November 9, 2026

Item 7.01Item EX-99.1NVCR overview

Short answer

NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer.

NovoCure Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer
  • Regulatory rejection reflects uncertainty over clinical benefit, not safety concerns
  • Novocure plans FDA discussions on approval pathways without additional clinical studies
  • Approval remains uncertain, creating commercialization and growth risk for the indication

Item EX-99.1 · Exhibit EX-99.1

  • FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from NSCLC after stereotactic radiation
  • FDA cited uncertainty about clinical benefit, not safety concerns
  • Novocure plans FDA discussions on approval pathways without additional clinical studies
  • Approval remains uncertain, delaying potential expansion of Optune Mya’s addressable market

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other NovoCure Ltd 8-K filings

Get the next NVCR 8-K as it lands

Follow NVCR for push alerts, or ask the research agent what this filing means.